



116

PATENT  
Attorney Docket No.: SALK2270-5  
(088802-5212)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Evans et al.

Application No.: 10/081,555

Confirmation No.: 6168

Filing Date: February 20, 2002

For: NOVEL STEROID-ACTIVATED  
NUCLEAR RECEPTORS AND USES  
THEREFOR

Group Art Unit: Unknown

Examiner: Unknown

**CERTIFICATE OF MAILING**

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450., on the date below.

\_\_\_\_\_  
Stephen E. Reiter  
Name of person mailing paper

  
\_\_\_\_\_  
Signature  
June 3, 2003  
\_\_\_\_\_  
Date

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT**

Sir:

In response to the Office communication dated January 3, 2003 (Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures), please consider the following amendments and remarks.

**Amendments to the Specification** begin on page 2 of this paper.

**Remarks** begin on page 5 of this paper.